[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"juvenile-rheumatoid-arthritis-jra\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:juvenile-rheumatoid-arthritis-jra":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":70,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":105},"100424417","unhide-project-a-digital-health-platform-to-collect-lifestyle-data-for-brain-inflammation-research-100424417",false,"NCT04806620","Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","Unhide® Project Also Known as The Unhide® Solve Together Unified Platform","Participants may be either self-diagnosed, or diagnosed by a physician with the following conditions:\n\n* Infection-associated chronic conditions such as Long COVID, chronic Lyme, myalgic encephalomyelitis (ME\u002FCFS), and post-acute neuropsychiatric syndrome (PANS\u002FPANDAS).\n* Neuroimmune, developmental, autonomic, and neurological conditions like migraines, dysautonomia, POTS, multiple sclerosis, and autism spectrum disorder.\n* Autoimmune diseases such as Lupus, Sjogren's Disease, rheumatoid arthritis, myasthenia gravis, ankylosing spondylitis, and related autoimmune conditions.\n\nInflammatory gastrointestinal conditions such as Crohn's Disease, Celiac Disease, and ulcerative colitis.\n\n* Behavioral and mood disorders such as anxiety, depression, bipolar disorder, PTSD, eating disorders, OCD, and other related conditions.\n* \"Healthy\" people (without brain inflammation), including unaffected individuals, unaffected individuals in the same household, and unaffected individuals who are married to relatives and family members.\n* Have consistent internet access and a cell phone, tablet, or PC since this is an online or app-based platform that requires entering data and completing surveys.\n* Currently live in the United States\n* Be able to participate in English (stay tuned for updates about the Spanish language version)\n* Be willing to share symptom and health data through the platform",true,"ALL","2 Years",{"count":20,"type":21},10000,"ESTIMATED","10 Years","OBSERVATIONAL","The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related neuroinflammatory conditions. Participants in the United States aged 2 years and older will provide self-reported health data, biometrics, and symptom diaries through the MyDataHelps™ app (branded as unhide® for this study). The goal is to create comprehensive longitudinal profiles to facilitate research into disease subtypes, causes, diagnostics, and potential treatments, as well as to identify potential participants for future optional studies. \"Healthy\" individuals without brain inflammation are also eligible to participate.\n\nThe digital health research platform used in this study was originally developed and designed by Solve M.E and was called SolveTogether. The Brain Inflammation Collaborative (BIC) expanded upon Solve M.E.'s work to include related diagnoses, pediatric participants, enhance symptom tracking, and more. BIC and Solve M.E. combined Solve Together and unhide®, to create The unhide® Solve Together Unified Platform in 2025.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69],"Post-Acute COVID-19 Syndrome","ME\u002FCFS","Rheumatic Arthritis","Juvenile Rheumatoid Arthritis (JRA)","Psoriatic Arthritis (PsA)","Ankylosing Spondylitis (AS)","Autoimmune Encephalitis","Celiac Disease","Celiac Disease in Children","Chronic Lyme Disease","Post-treatment Lyme Disease Syndrome","Crohn's Disease","Dysautonomia","Anorexia Nervosa","Bulimia Nervosa","ARFID","Avoidant \u002F Restrictive Food Intake Disorder","Ehlers Danlos Syndrome","Endometriosis","Fibromyalgia (FM)","Long COVID","Lupus","Migraines","Mast Cell Activation Syndrome","Multiple Sclerosis","Myalgic Encephalomyelitis (ME)","Myasthenia Gravis, Generalized","Myasthenia Gravis in Children","Narcolepsy","Obsessive Compulsive Disorder (OCD)","PANDAS","Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)","POTS - Postural Orthostatic Tachycardia Syndrome","General Anxiety Disorder, Social Anxiety Disorder","PTSD - Post Traumatic Stress Disorder","Psoriasis","Traumatic Brain Injury","Tourette's Syndrome","Inflammatory Bowel Disease (IBD)","Autoimmune Diseases","Neurological Diseases or Conditions","Psychiatric Disorder","Sjogren's Syndrome","Ulcerative Colitis and Crohn's Disease",[46,71,72,73,74,75,76,77,78,79,27,80,81,82,83,84,48,85,86,87,88,89,90,91,92],"Myalgic Encephalomyelitis","Chronic Fatigue Syndrome","Longitudinal Natural History Study","Observational","Neuroinflammatory Disease","Brain inflammation","Neuroinflammatory disorders","PANS\u002FPANDAS","Autoimmune encephalitis","Dysautonomia \u002F POTS","Multiple sclerosis","Autoimmune disease","Inflammatory bowel disease (Crohn's, ulcerative colitis)","Celiac disease","Mood disorders (anxiety, depression, bipolar, PTSD, OCD)","Mobile health app","Patient registry","Wearable devices","Fatigue","Post-exertional malaise","Brain Fog","Mental health","RECRUITING","2026-01-20",{"date":96,"type":97},"2026-01-22","ACTUAL",{"date":99,"type":97},"2023-07-05",{"date":101,"type":21},"2030-12-31",{"name":103,"class":104},"Brain Inflammation Collaborative","OTHER",1,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":118,"phases":119,"briefSummary":121,"conditions":122,"keywords":129,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":105},"100206313","phase-2-reduced-intensity-conditioning-for-non-malignant-disorders-undergoing-ucbt-bmt-or-pbsct-100206313","NCT01962415","Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT","A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation","HSCT+RIC","Inclusion:\n\n1. A 4\u002F6, 5\u002F6 or 6\u002F6 HLA matched related or unrelated UCB unit available that will deliver a pre-cryopreservation total nucleated cell dose of ≥ 3 x 10e7 cells\u002Fkg, or double unit grafts, each cord blood unit delivering at least 2 x 10e7 cells\u002Fkg OR an 8 of 8 or 7 of 8 HLA allele level matched unrelated donor bone marrow or peripheral blood progenitor graft.\n2. Adequate organ function as measured by:\n\n   1. Creatinine ≤ 2.0 mg\u002FdL and creatinine clearance ≥ 50 mL\u002Fmin\u002F1.73 m2.\n   2. Hepatic transaminases (ALT\u002FAST) ≤ 4 x upper limit of normal (ULN).\n   3. Adequate cardiac function by echocardiogram or radionuclide scan (shortening fraction \\> 26% or ejection fraction \\> 40% or \\> 80% of normal value for age).\n   4. Pulmonary evaluation testing demonstrating CVC or FEV1\u002FFVC of ≥ 50% of predicted for age and\u002For resting pulse oximeter ≥ 92% on room air or clearance by the pediatric or adult pulmonologist. For adult patients DLCO (corrected for hemoglobin) should be ≥ 50% of predicted if the DLCO can be obtained.\n3. Written informed consent and\u002For assent according to FDA guidelines.\n4. Negative pregnancy test if pubertal and\u002For menstruating.\n5. HIV negative.\n6. A non-malignant disorder amenable to treatment by stem cell transplantation, including but not limited to:\n\n   1. Primary Immunodeficiency syndromes including but not limited to:\n\n      * Severe Combined Immune Deficiency (SCID) with NK cell activity\n      * Omenn Syndrome\n      * Bare Lymphocyte Syndrome (BLS)\n      * Combined Immune Deficiency (CID) syndromes\n      * Combined Variable Immune Deficiency (CVID) syndrome\n      * Wiskott-Aldrich Syndrome\n      * Leukocyte adhesion deficiency\n      * Chronic granulomatous disease (CGD)\n      * X-linked Hyper IgM (XHIM) syndrome\n      * IPEX syndrome\n      * Chediak - Higashi Syndrome\n      * Autoimmune Lymphoproliferative Syndrome (ALPS)\n      * Hemophagocytic Lymphohistiocytosis (HLH) syndromes\n      * Lymphocyte Signaling defects\n      * Other primary immune defects where hematopoietic stem cell transplantation may be beneficial\n   2. Congenital bone marrow failure syndromes including but not limited to:\n\n      * Dyskeratosis Congenita (DC)\n      * Congenital Amegakaryocytic Thrombocytopenia (CAMT)\n      * Osteopetrosis\n   3. Inherited Metabolic Disorders (IMD) including but not limited to:\n\n      * Mucopolysaccharidoses\n\n        * Hurler syndrome (MPS I)\n        * Hunter syndrome (MPS II)\n      * Leukodystrophies\n\n        * Krabbe Disease, also known as globoid cell leukodystrophy\n        * Metachromatic leukodystrophy (MLD)\n        * X-linked adrenoleukodystrophy (ALD)\n        * Hereditary diffuse leukoencephalopathy with spheroids (HDLS)\n      * Other inherited metabolic disorders\n\n        * alpha mannosidosis\n        * Gaucher Disease\n      * Other inheritable metabolic diseases where hematopoietic stem cell transplantation may be beneficial.\n   4. Hereditary anemias\n\n      * Thalassemia major\n      * Sickle cell disease (SCD) - patients with sickle disease must have one or more of the following:\n\n        * Overt or silent stroke\n        * Pain crises ≥ 2 episodes per year for past year\n        * One or more episodes of acute chest syndrome\n        * Osteonecrosis involving ≥ 1 joints\n        * Priapism\n      * Diamond Blackfan Anemia (DBA)\n      * Other congenital transfusion dependent anemias\n   5. Inflammatory Conditions\n\n      * Crohn's Disease\u002FInflammatory Bowel Disease\n\nExclusion:\n\n1. Allogeneic hematopoietic stem cell transplant within the previous 6 months.\n2. Any active malignancy or MDS.\n3. Severe acquired aplastic anemia.\n4. Uncontrolled bacterial, viral or fungal infection (currently taking medication and with progression of clinical symptoms).\n5. Pregnancy or nursing mother.\n6. Poorly controlled pulmonary hypertension.\n7. Any condition that precludes serial follow-up.","2 Months","55 Years",{"count":117,"type":21},100,"INTERVENTIONAL",[120],"PHASE2","The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant (BMT) or peripheral blood stem cell transplant (PBSCT) in patients with non-malignant disorders that are amenable to treatment with hematopoietic stem cell transplant (HSCT). After transplant, subjects will be followed for late effects and for ongoing graft success.",[123,124,125,126,127,128,29],"Primary Immunodeficiency (PID)","Congenital Bone Marrow Failure Syndromes","Inherited Metabolic Disorders (IMD)","Hereditary Anemias","Inflammatory Conditions","Systemic Juvenile Idiopathic Arthritis (sJIA)",[130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,37,159,160,161,162,163,128,29],"Severe Combined Immune Deficiency (SCID)","Omenn Syndrome","Bare Lymphocyte Syndrome (BLS)","Combined Immune Deficiency (CID) syndromes","Combined Variable Immune Deficiency (CVID) syndrome","Wiskott-Aldrich Syndrome","Leukocyte adhesion deficiency","Chronic granulomatous disease (CGD)","X-linked Hyper IgM (XHIM) syndrome","IPEX syndrome","Chediak - Higashi Syndrome","Autoimmune Lymphoproliferative Syndrome (ALPS)","Hemophagocytic Lymphohistiocytosis (HLH) syndromes","Lymphocyte Signaling defects","Dyskeratosis Congenita (DC)","Congenital Amegakaryocytic Thrombocytopenia (CAMT)","Osteopetrosis","Mucopolysaccharidoses","Hurler syndrome (MPS I)","Hunter syndrome (MPS II)","Leukodystrophies","Krabbe Disease","Metachromatic leukodystrophy (MLD)","X-linked adrenoleukodystrophy (ALD)","Alpha mannosidosis","Gaucher Disease","Thalassemia major","Sickle cell disease (SCD)","Diamond Blackfan Anemia (DBA)","Inflammatory Bowel Disease","Hematopoietic Stem Cell Transplant (HSCT)","Congenital transfusion dependent anemias","Globoid cell leukodystrophy","Hereditary diffuse leukoencephalopathy with spheroids (HDLS)","2025-12-08",{"date":166,"type":97},"2025-12-15",{"date":168,"type":97},"2014-02-04",{"date":170,"type":21},"2027-11",{"name":172,"class":104},"Paul Szabolcs"]